|
|
|||||||||||||
|
|
||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original articles |
1 University of York, United Kingdom
2 University of Leeds, United Kingdom
3 University of Reading, United Kingdom
4 University of Oxford, United Kingdom
* To whom correspondence should be addressed. E-mail: mew3{at}york.ac.uk.
Accepted 25 April 2007
| Abstract |
|---|
Objective: To determine the effectiveness and cost-effectiveness of height screening (aged four to 11) to identify height-related conditions.
Design: Systematic review and economic modelling.
Setting and intervention: We included published and un-published studies of any design except case reports, conducted in any setting that measured childrens height as part of a population-level assessment. Studies were identified by electronic database searches, contact with experts and from bibliographies of retrieved studies.
Participants: Children aged between four and 11 years
Outcome measures: Diagnostic yield of height-related conditions and change in quality of life, as measured by Quality-adjusted Life Years (QALYs), for early versus late treatment of underlying conditions.
Results: Twelve studies described a height screening programme and provided data on the diagnostic yield of newly diagnosed height-related conditions. Where reported, yield for Growth Hormone Deficiency (per 1000 children screened) ranged from 0.05 (1/20,000) to 0.62 (approximately 1/1500) and for Turner syndrome (per 1000 children screened) was between 0.02 (1/50,000) and 0.07 (approximately 1/14,000). As a secondary gain, children with other potentially treatable conditions were identified; diagnostic yields ranged from 0.22 to 1.84 per 1000 children screened. Three studies did not detect any new cases, but all of these studies had methodological limitations. Economic modelling suggested that height screening is associated with health improvements and is cost effective for a willingness to pay threshold of £30,000 per QALY.
Conclusions: This review indicates the utility and acceptable cost-effectiveness of height screening arising from increased detection of height-related disorders and secondary pick-up of other undiagnosed conditions. However, further research is needed to obtain more reliable data on quality of life gains and costs associated with early interventions for height-related conditions. The exact role of height screening programmes in improving child health remains to be determined.
Keywords: child development, growth, mass screening, systematic review
Related Article
This article has been cited by other articles:
![]() |
D Hall, T Cole, D Elliman, P Gibson, S Logan, and J Wales Growth monitoring Arch. Dis. Child., August 1, 2008; 93(8): 717 - 718. [Full Text] [PDF] |
||||
![]() |
T. Fry If it's worth doing, let's do it! Arch. Dis. Child., April 1, 2008; 93(4): 267 - 268. [Full Text] [PDF] |
||||
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | REGISTER |
| ARCH DIS CHILD | FETAL NEONATAL ED | ED PRACTICE |